Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

被引：44

作者：

Stahl, Stephen M. ^{[1
,2
,3
,4
,5
,6
,7
,8
,9
,10
,11
,12
,13
,14
,15
,16
,17
,18
,19
,20
,21
,22
,23
,24
,25
,26
,27
,28
,29
,30
,31
,32
,33
,34
,35
,36
,37
,38
,39
,40
,41
,42
,43
,44
,45
,46
,47
,48
,49
,50
,51
,52
,53
,54
,55
,56
,57
,58
]}

机构：

[1] Univ Calif San Diego, Psychiat, La Jolla, CA 92093 USA

[2] Univ Cambridge, Cambridge, England

[3] Calif Dept State Hosp, Psychopharmacol, Sacramento, CA 95814 USA

[4] Acadia, San Diego, CA USA

[5] Adamas, Emeryville, CA USA

[6] Alkermes, Dublin, Ireland

[7] Allergan, Dublin, Ireland

[8] Arbor Pharmaceutcials, Atlanta, GA USA

[9] AstraZeneca, Cambridge, England

[10] Avanir, Aliso Viejo, CA USA

[11] Axovant, Hamilton, Bermuda

[12] Axsome, New York, NY USA

[13] Biogen, Cambridge, MA USA

[14] Biomarin, Novato, CA USA

[15] Biopharma, Cary, NC USA

[16] Celgene, Summit, NJ USA

[17] Concert, Bristol, Avon, England

[18] ClearView, Princeton, NJ USA

[19] DepoMed, Newark, CA USA

[20] Dey, Wayne, NJ USA

[21] EnVivo, Watertown, MA USA

[22] EMD Serono, Rockland, MA USA

[23] Ferring, St Prex, Switzerland

[24] Forest, New York, NY USA

[25] Forum, Watertown, MA USA

[26] Genomind, King Of Prussia, PA USA

[27] Innovat Sci Solut, Morristown, NJ USA

[28] Intra Cellular Therapies, New York, NY USA

[29] Janssen, Beerse, Belgium

[30] Jazz, Dublin, Ireland

[31] Lilly, Indianapolis, IN USA

[32] Lundbeck, Copenhagen, Denmark

[33] Merck, Kenilworth, NJ USA

[34] Neos, Grand Prairie, TX USA

[35] Novartis, Basel, Switzerland

[36] Noveida, New York, NY USA

[37] Orexigen, La Jolla, CA USA

[38] Otsuka, San Francisco, CA USA

[39] PamLabs, Carlsbad, CA USA

[40] Perrigo, Dublin, Ireland

[41] Pfizer, New York, NY USA

[42] Pierre Fabre, Paris, France

[43] Reviva, Paris, France

[44] Servier, Neuilly Sur Seine, France

[45] Shire, Lexington, MA USA

[46] Sprout, Chicago, IL USA

[47] Sunovion, London, England

[48] Taisho, Toshima, Tokyo, Japan

[49] Taliaz, Tel Aviv, Israel

[50] Teva, Petah Tiqwa, Israel

来源：

CNS SPECTRUMS | 2019年 / 24卷 / 05期

关键词：

MAJOR DEPRESSIVE DISORDER; ANTIDEPRESSANT MEDICATIONS; AMPA RECEPTORS; PATHOPHYSIOLOGY; LEVOMETHORPHAN; KETAMINE;

D O I：

10.1017/S1092852919001470

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies targeting monoamines. The recent approval of the NMDA (N-methyl-d-aspartate) antagonist esketamine given intranasally for treatment-resistant depression has reinforced the need for agents with rapid onset with alternate mechanisms of action. Dextromethorphan/bupropion, an investigational medicine currently in development, is one such candidate.

引用

页码：461 / 466

页数：6

共 50 条

[31] CEREBROSPINAL-FLUID AND SERUM CONCENTRATIONS OF THE N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST MEMANTINE IN MAN
KORNHUBER, J
QUACK, G
NEUROSCIENCE LETTERS, 1995, 195 (02) : 137 - 139
[32] CARDIOVASCULAR EFFECTS OF AN N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST, MK-801 IN CONSCIOUS RATS
LEWIS, SJ
BARRES, C
JACOB, HJ
BRODY, MJ
HYPERTENSION, 1988, 12 (03) : 342 - 342
[33] Memantine, a N-methyl-D-Aspartate (NMDA) receptor antagonist, as a promising drug in preclinical neuropathic pain development
Morel, V.
Pickering, G.
Etienne, M.
Dupuis, A.
Privat, A. M.
Wattiez, A. S.
Chalus, M.
Eschalier, A.
Daulhac, L.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 34 - 34
[34] Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist -: a review of preclinical data
Parsons, CG
Danysz, W
Quack, G
NEUROPHARMACOLOGY, 1999, 38 (06) : 735 - 767
[35] Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist
Zucchini, S
Buzzi, A
Bergamaschi, M
Pietra, C
Villetti, G
Simonato, M
NEUROREPORT, 2002, 13 (16) : 2071 - 2074
[36] OXINDOLE N-METHYL-D-ASPARTATE (NMDA) ANTAGONISTS
CHENARD, BL
BUTLER, TW
SHALABY, IA
PROCHNIAK, MA
KOE, BK
FOX, CB
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (01) : 91 - 94
[37] Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R
Blandl, T
Zajicek, J
Prorok, M
Castellino, FJ
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) : 7391 - 7396
[38] OXINDOLE N-METHYL-D-ASPARTATE (NMDA) ANTAGONISTS
BUTLER, TW
CHENARD, BL
SHALABY, IA
PROCHNIAK, MA
KOE, BK
FOX, CB
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 204 : 69 - MEDI
[39] N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics
Brown, Dean G.
Krupp, Johannes J.
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (08) : 749 - 770
[40] Assembly of N-methyl-D-aspartate (NMDA) receptors
McIlhinney, RAJ
Philipps, E
Le Bourdelles, B
Grimwood, S
Wafford, K
Sandhu, S
Whiting, P
BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 865 - 868

← 1 2 3 4 5 →